Clovis Oncology, Inc.

BOULDER, CO How do I update this listing?

Clovis Oncology is based out of Boulder. Clovis Oncology, Inc. develops and commercializes anti-cancer pharmaceutical drugs. The company develops CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine, which is in Phase III clinical trials for first-line treatment of metastatic pancreatic cancer; Phase II clinical trials for second-line treatment of metastatic pancreatic cancer; and preclinical trials for solid tumors. Its products also include CO-1686, a small molecule epidermal growth factor receptor, which is in preclinical trials for the treatment of non-small cell lung cancer; and CO-338, a small molecule PARP inhibitor, which is in Phase II clinical trials for the adjuvant treatment of hereditary, or germ-line, BRCA mutant, and triple-negative breast cancer, as well as Phase I clinical trials for the treatment of solid tumors. The company intends to sell its products through distributors in the United States, Europe, and internationally. Clovis Oncology, Inc. was founded in 2009 and is based in Boulder, Colorado.Whalewisdom has at least 1 13G filings, and 145 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2013-11-27. The notice included securities offered of Equity

Create Alert

Contact Info

clovis oncology, inc.
5500 FLATIRON PARKWAY
BOULDER CO    80301

Business Phone: (303) 625-5000
SEC SIC CODE:
2834-PHARMACEUTICAL PREPARATIONS

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form to be used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2013-11-27 D PHARMACEUTICALS Equity INDEFINITE 191,962,756 INDEFINITE
2011-06-02 D PHARMACEUTICALS Debt,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security,Other INDEFINITE 20,000,000 INDEFINITE
2011-05-18 D/A PHARMACEUTICALS Equity 146,300,000 146,300,000 0
2010-05-19 D PHARMACEUTICALS Equity 146,300,000 146,300,000 0
2009-06-25 D PHARMACEUTICALS Equity 146,300,000 146,300,000 0
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
ANDREW R. ALLEN subscription required
    EXECUTIVE OFFICER
BRIAN G. ATWOOD subscription required
    DIRECTOR
EDWARD J. MCKINLEY subscription required
    DIRECTOR
ERLE T. MAST subscription required
    EXECUTIVE OFFICER
GILLIAN C. IVERS-READ subscription required
    EXECUTIVE OFFICER
GINGER L. GRAHAM subscription required
    DIRECTOR
JAMES C. BLAIR subscription required
    DIRECTOR
KEITH FLAHERTY subscription required
    DIRECTOR
M. JAMES BARRET subscription required
    DIRECTOR
PATRICK J. MAHAFFY subscription required
    EXECUTIVE OFFICER
PAUL KLINGENSTEIN subscription required
    DIRECTOR
STEVEN L. HOERTER subscription required
    EXECUTIVE OFFICER
THORLEF SPICKSCHEN subscription required
    DIRECTOR

Elevate your investments